Trends in lipid management among patients with coronary artery disease

被引:38
作者
Massing, MW
Foley, KA
Sueta, CA
Chowdhury, M
Biggs, DP
Alexander, CM
Simpson, RJ
机构
[1] Med Review N Carolina, Cary, NC 27511 USA
[2] Univ N Carolina, Sch Publ Hlth, Chapel Hill, NC USA
[3] Merck & Co Inc, Outcomes Res & Management, West Point, PA USA
[4] Univ N Carolina, Sch Med, Chapel Hill, NC USA
关键词
D O I
10.2337/diacare.26.4.991
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective- To examine lipid management trends for coronary artery disease (CAD) patients with and without diabetes in order to determine whether those with diabetes are beginning to receive aggressive lipid management consistent with their elevated risk. Research Design and Methods-We used outpatient medical record data from 47,813 CAD patients seen at 295 medical practices participating in the Quality Assurance Program II between 1996 and 1998. Lipid testing rates, lipid treatment rates, and serum lipid concentrations are described for CAD patients with and without diabetes within strata of office visit date. Results-Lipid testing and treatment rates increased and mean lipid levels decreased markedly over time. Those with diabetes were 26% less likely to have a lipid profile and 17% less likely to receive a lipid-lowering medication than their nondiabetic counterparts, and this disparity did not diminish over time. Among treated patients, mean non-HDL cholesterol (non-HDL-C) and LDL cholesterol (LDL-C) declined less rapidly over time for patients wit without diabetes. Conclusions-Although impressive progress was made in the outpatient lipid management of CAD patients, lipid management for CAD patients with diabetes improved no more rapidly, and in some cases less rapidly, than for nondiabetic patients. Given their higher risk, more effort is needed to ensure that CAD patients with diabetes receive aggressive lipid management.
引用
收藏
页码:991 / 997
页数:7
相关论文
共 31 条
[1]  
*AM DIAB ASS, 2002, MAK LINK DIAB HEART
[2]  
American Diabetes Association, 2002, DIABETES CARE, V25, pS74, DOI DOI 10.2337/DIACARE.25.2007.S74
[3]  
[Anonymous], 1995, Diabetes in America
[4]  
Calder R, 2000, PRACTICAL DIABETOLOG, V19, P7
[5]   Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) [J].
Cleeman, JI ;
Grundy, SM ;
Becker, D ;
Clark, LT ;
Cooper, RS ;
Denke, MA ;
Howard, WJ ;
Hunninghake, DB ;
Illingworth, DR ;
Luepker, RV ;
McBride, P ;
McKenney, JM ;
Pasternak, RC ;
Stone, NJ ;
Van Horn, L ;
Brewer, HB ;
Ernst, ND ;
Gordon, D ;
Levy, D ;
Rifkind, B ;
Rossouw, JE ;
Savage, P ;
Haffner, SM ;
Orloff, DG ;
Proschan, MA ;
Schwartz, JS ;
Sempos, CT ;
Shero, ST ;
Murray, EZ .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 285 (19) :2486-2497
[6]  
Collins R, 2002, LANCET, V360, P7, DOI 10.1016/S0140-6736(02)09327-3
[7]   Type 2 diabetes mellitus - Greater cardiovascular risks and greater benefits of therapy [J].
Fagan, TC ;
Sowers, J .
ARCHIVES OF INTERNAL MEDICINE, 1999, 159 (10) :1033-1034
[8]   Improved treatment of coronary heart disease by implementation at a Cardiac Hospitalization Atherosclerosis Management Program (CHAMP) [J].
Fonarow, GC ;
Gawlinski, A ;
Moughrabi, S ;
Tillisch, IH .
AMERICAN JOURNAL OF CARDIOLOGY, 2001, 87 (07) :819-822
[9]   Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction [J].
Haffner, SM ;
Lehto, S ;
Rönnemaa, T ;
Pyörälä, K ;
Laakso, M .
NEW ENGLAND JOURNAL OF MEDICINE, 1998, 339 (04) :229-234
[10]  
Huse DM, 2001, ANN PHARMACOTHER, V35, P1173